Purpose: Recent studies have revealed recurrent alterations in the cell adhesion gene FAT4, a candidate tumor suppressor gene, in cancer. FAT atypical cadherin 4 (FAT4) is a transmembrane receptor involved in the Hippo signaling pathway, which is involved in the control of organ size. Here, we investigated the loss of FAT4 expression and its association with clinicopathological risk factors in gastric cancer.
Introduction
Despite developments in surgical techniques and improvements in the efficacies of anticancer drugs in recent years, gastric cancer (GC) remains one of the most common malignancies and the second most common cause of cancer-related deaths worldwide. 1 Therefore, the identification of new diagnostic or prognostic biomarkers for GC is one of the major goals in this field.
Recent whole-exome sequencing studies have revealed a number of potential cancer-driving genes in GC. Among the frequently mutated cell-adhesion genes, FAT4 was particularly notable, ranking fourth in mutational significance after PKHD1, CTNNB1, and CNTN1. 2 The family of FAT genes consists of the human homologs of the Drosophila Fat gene, which is involved in tumor suppression, 3 control of cell proliferation during Drosophila development, and planar cell polarity. 4 In addition, Fat was recently found to be a potential transmembrane receptor in the Hippo signaling pathway in Drosophila, which plays an important role in controlling organ size. 5 In Drosophila, Fat inactivation causes hyperplasia of pupal imaginal discs, and loss-of-function mutations give rise to hyperplastic tumors through increased cell proliferation and decreased cell death. 6 There are four members in the FAT atypical cadherin (FAT) family in humans (FAT1, FAT2, FAT3, and FAT4 
Tissue microarrays
Tissue microarrays (TMAs) were constructed by reviewing hematoxylin and eosin slides, and selecting one representative formalin-fixed paraffin-embedded (FFPE) archival block for each case.
Core tissue biopsies (2 mm in diameter) were taken from individual FFPE blocks (donor blocks) and arranged in recipient paraffin blocks (tissue array blocks) using a trephine. In addition, normal gastric mucosa was obtained in 16 cases using the same procedure.
Three array blocks containing 136 GC and 16 normal gastric tissue samples were prepared.
Immunohistochemistry and staining evaluation
The expression of FAT4 in normal gastric mucosa and GCs was evaluated using immunohistochemistry. Tissue sections (4 μm)
were cut from the TMAs, deparaffinized in xylene, and hydrated using an ethanol-deionized water series. Endogenous peroxidase activity was blocked using 3% H 2 O 2 in methanol for 15 minutes. 
Statistical analysis
To evaluate the relationship between FAT4 expression and clinicopathological parameters, the Pearson chi-square test was used for parametric analysis whereas Fisher exact test, Mann-Whitney test,
and Kruskal-Wallis test were applied for nonparametric analysis.
Overall survival (OS) and disease-free survival (DFS) rates according to FAT4 expression were calculated using Kaplan-Meier analysis. To assess differences between Kaplan-Meier curves, the log-rank test was used. DFS was calculated in all but 5 patients of stage IV according to the 7th AJCC staging system. 
Loss of FAT4 expression in gastric cancer
The evaluation of FAT4 expression in 16 normal gastric mucosa samples and 136 GC samples was shown in Fig. 1 
Association of loss of FAT4 expression with clinicopathological parameters in gastric cancer

Discussion
During organ development, the number of cells in growing tissues is tightly controlled by the regulation of cellular proliferation and apoptosis to maintain a proper organ size and a specific organ shape. This is orchestrated by numerous developmental genes.
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The dysregulation of developmental genes is often implicated in human diseases. For example, FAT1, an isoform of the atypical cadherin, has been reported to induce liver fibrosis, which is also However, our study showed the loss of FAT4 expression in a higher proportion of GCs (24.3%) as compared with the 5% gene mutations and 4% deletions of FAT4 in GCs reported in the previous study. 2 These differences might be explained by epigenetic regulation or post-transcriptional modification. The mouse Fat4 gene is inactivated by a loss of heterozygosity and promoter CpG hypermethylation in subcutaneous tumors induced by random chromosomal deletion. 13 Additionally, human FAT4 mRNA expression has been found to be repressed in breast cancer, in part by promoter CpG hypermethylation. 13 The FAT4 promoter has also been found to be hypermethylated in a subset of stage I lung adenocarcinoma, and FAT4 mRNA is downregulated in stage I/II non-small cell lung cancer. 
